GlassScriptPhysician profile
Cyril Ruwende
NPI 1376629386
$3,073.15
in general payments reported to CMS, 2019-2025
22 companies · $595 in 2025
The $595 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,871 · 2020: $76.04 · 2021: $63.22 · 2022: $70.07 · 2023: $140 · 2024: $257 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $992.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,699.12 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $208.74 | 2023-2025 | Perclose Prostyle, Pressurewire, Xience Skypoint |
| Medtronic Vascular, INC. | $162.37 | 2019-2020 | |
| Impulse Dynamics (USA) INC. | $155.20 | 2025 | Optimizer |
| Cordis US Corp. | $146.45 | 2024-2025 | Mynx Control Venous, Mynx Control |
| Boston Scientific Corporation | $118.52 | 2024-2025 | Rotapro |
| Cardiovascular Systems INC. | $96.99 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $72.95 | 2023-2024 | Assure Wcd |
| Janssen Pharmaceuticals, INC | $55.34 | 2020-2022 | |
| Biotronik INC. | $49.74 | 2025 | Acticor 7 Vr-T Dx |
| Abiomed | $44.82 | 2025 | |
| Pfizer INC. | $40.60 | 2019-2025 | |
| Bridgebio Pharma, INC. | $34.97 | 2025 | Attruby |
| Medtronic, INC. | $30.32 | 2022-2023 | Cobalt Dr Mri Surescan |
| Kiniksa Pharmaceuticals International, Plc | $25.83 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $23.96 | 2019 | |
| Bard Peripheral Vascular, INC. | $23.78 | 2021 | |
| Merck Sharp & Dohme LLC | $19.22 | 2022 | |
| Janssen Scientific Affairs, LLC | $18.75 | 2019 | |
| Atricure, INC. | $17.94 | 2024 | |
| Baxter Healthcare | $13.78 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Cathworks, INC. | $13.76 | 2025 | Ffrangio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyril Ruwende listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.